Clarity Pharmaceuticals' Prostate Cancer Trial to Continue Without Changes to Protocol
MT Newswires Live
Jan 15
Clarity Pharmaceuticals (ASX:CU6) is set to advance its SECuRE trial to the phase II cohort expansion phase with no changes to the protocol, following a recommendation by the safety review committee, according to a Thursday filing with the Australian bourse.
The trial evaluates the company's targeted copper theranostic product, 67Cu-SAR-bisPSMA, for the treatment of prostate cancer, the filing said.
The interim results assessed by the committee from nine participants who had evaluable data by Nov. 25, 2025, showed promising efficacy and a favorable safety profile for 67Cu-SAR-bisPSMA.
The trial will continue enrollment in the cohort expansion phase, with recruitment completion expected this year, as per the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.